Is Cell Point overvalued or undervalued?

As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30. These ratios suggest that Cell Point is trading at a significant premium compared to its earnings and cash flow metrics.
In comparison to its peers, Cell Point's valuation stands out starkly; for instance, PTC India, which is deemed very attractive, has a PE ratio of just 7.52, while Elitecon International is categorized as very expensive with a PE of 309.88. This stark contrast highlights Cell Point's overvaluation in the retailing sector. Additionally, despite a recent uptick in stock price, the year-to-date return of -27.1% significantly underperforms the Sensex's 9.58% return, further reinforcing the notion that Cell Point may not be a sound investment at its current valuation level.